1 research outputs found
ΠΠΈΠ·Π°ΡΠ½ Π½Π° ΡΠΈΠ·ΠΈΠ±ΠΈΠ»ΠΈΡΠΈ ΡΡΡΠ΄ΠΈΡΠ° Π·Π° Π²ΠΎΡΠΏΠΎΡΡΠ°Π²ΡΠ²Π°ΡΠ΅ Π½Π° ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²ΠΎ Π½Π° zirconium-89 ΡΠ°Π΄ΠΈΠΎΠΈΠ·ΠΎΡΠΎΠΏ ΠΈ ΠΈΠΌΠΏΠ»Π΅ΠΌΠ΅Π½ΡΠ°ΡΠΈΡΠ° Π½Π° 89Zr-ΡΠ°Π΄ΠΈΠΎΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠΈ Π²ΠΎ ΠΊΠ»ΠΈΠ½ΠΈΡΠΊΠ°ΡΠ° ΠΏΡΠ°ΠΊΡΠ° Π²ΠΎ Π Π΅ΠΏΡΠ±Π»ΠΈΠΊΠ° Π‘Π΅Π²Π΅ΡΠ½Π° ΠΠ°ΠΊΠ΅Π΄ΠΎΠ½ΠΈΡΠ°
In the last decade, the application of radiopharmaceuticals based on zirconium-89 (89Zr) radiometal has increased in both preclinical and clinical studies. The most frequently used 89Zr-radiopharmaceutical is 89Zr-trastuzumab used in the management of patients with breast cancer. Breast cancer is the most common cancer among women in North Macedonia and the most common cause of death from malignant neoplasms in this population; therefore, the introduction of new nuclear medicine procedures in these patients might improve the management of this disease. However,the introduction of radioisotope and radiopharmaceutical production requires significant investments, both manpower and financial. The purpose of this work is to present the design conceptualization of a feasibility study for the establishment of production of zirconium-89 radioisotope and implementation of 89Zr-radiopharmaceuticals in clinical practice in the Republic of North Macedonia and to present the initial results from the first phases of the study. This feasibility study is designed to include preliminary analysis, market research, technical feasibility analysis, economic analysis, review and analysis of all data and feasibility conclusion. The evaluation of the data from the analyses conducted in all study phases is needed to identify the favourable and unfavourable factors and circumstances in order to make a final assessment of the feasibility of establishing the zirconium-89 radioisotope and 89Zr-radiopharmaceuticals production and implementation of 89Zr-trastuzumab use in nuclear medicine practice.ΠΠΎ ΠΏΠΎΡΠ»Π΅Π΄Π½Π°ΡΠ° Π΄Π΅ΡΠ΅Π½ΠΈΡΠ°, ΡΠ°Π΄ΠΈΠΎΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΡΠΊΠΈΡΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΈ ΡΡΠΎ ΡΠΎΠ΄ΡΠΆΠ°Ρ zirconium-89 (89Zr) ΡΠ°Π΄ΠΈΠΎΠΈΠ·ΠΎΡΠΎΠΏ ΠΈΠΌΠ°Π°Ρ Π·Π³ΠΎΠ»Π΅ΠΌΠ΅Π½Π° ΠΏΡΠΈΠΌΠ΅Π½Π° ΠΊΠ°ΠΊΠΎ Π²ΠΎ ΠΏΡΠ΅ΡΠΊΠ»ΠΈΠ½ΠΈΡΠΊΠΈΡΠ΅, ΡΠ°ΠΊΠ° ΠΈ Π²ΠΎ ΠΊΠ»ΠΈΠ½ΠΈΡΠΊΠΈΡΠ΅ ΡΡΡΠ΄ΠΈΠΈ. ΠΠ°ΡΡΠ΅ΡΡΠΎ ΠΊΠΎΡΠΈΡΡΠ΅Π½ 89Zr-ΡΠ°Π΄ΠΈΠΎΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΠΊ Π΅ 89Zr-trastuzumab ΠΊΠΎΡ ΡΠ΅ ΠΏΡΠΈΠΌΠ΅Π½ΡΠ²Π° Π²ΠΎ Π½Π°ΡΠΎΠΊΠ° Π½Π° ΠΏΠ»Π°Π½ΠΈΡΠ°ΡΠ΅ Π½Π° ΡΠ΅ΡΠ°ΠΏΠΈΡΠ° Π½Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ ΡΠΎ ΡΠ°ΠΊ Π½Π° Π΄ΠΎΡΠΊΠ°. Π Π°ΠΊΠΎΡ Π½Π° Π΄ΠΎΡΠΊΠ°ΡΠ° Π΅ Π½Π°ΡΡΠ΅ΡΡΠΈΠΎΡ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌ ΠΊΠ°Ρ ΠΆΠ΅Π½ΠΈΡΠ΅ Π²ΠΎ Π‘Π΅Π²Π΅ΡΠ½Π° ΠΠ°ΠΊΠ΅Π΄ΠΎΠ½ΠΈΡΠ° ΠΈ Π½Π°ΡΡΠ΅ΡΡΠ° ΠΏΡΠΈΡΠΈΠ½Π° Π·Π° ΡΠΌΡΡ ΠΎΠ΄ ΠΌΠ°Π»ΠΈΠ³Π½ΠΈ Π½Π΅ΠΎΠΏΠ»Π°Π·ΠΌΠΈ ΠΊΠ°Ρ ΠΎΠ²Π°Π° ΠΏΠΎΠΏΡΠ»Π°ΡΠΈΡΠ°, Π·Π°ΡΠΎΠ° Π²ΠΎΠ²Π΅Π΄ΡΠ²Π°ΡΠ΅ΡΠΎ Π½ΠΎΠ²ΠΈ Π΄ΠΈΡΠ°Π³Π½ΠΎΡΡΠΈΡΠΊΠΈ ΠΏΡΠΎΡΠ΅Π΄ΡΡΠΈ Π²ΠΎ Π½ΡΠΊΠ»Π΅Π°ΡΠ½Π°ΡΠ° ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Π° ΠΌΠΎΠΆΠ΅ Π΄Π° ΠΏΡΠΈΠ΄ΠΎΠ½Π΅ΡΠ΅ Π·Π° ΠΏΠΎΠ΄ΠΎΠ±ΡΠΎ ΠΏΠ»Π°Π½ΠΈΡΠ°ΡΠ΅ Π½Π° ΡΠ΅ΡΠ°ΠΏΠΈΡΠ°ΡΠ° ΠΊΠ°Ρ ΠΎΠ²ΠΈΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΈ. Π‘Π΅ΠΏΠ°ΠΊ, Π²ΠΎΡΠΏΠΎΡΡΠ°Π²ΡΠ²Π°ΡΠ΅ΡΠΎ Π½Π° ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²ΠΎ Π½Π° ΡΠ°Π΄ΠΈΠΎΠΈΠ·ΠΎΡΠΎΠΏΠΈ ΠΈ ΡΠ°Π΄ΠΈΠΎΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠΈ Π±Π°ΡΠ° Π·Π½Π°ΡΠΈΡΠ΅Π»Π½ΠΈ ΠΈΠ½Π²Π΅ΡΡΠΈΡΠΈΠΈ, ΡΠΈΠ½Π°Π½ΡΠΈΡΠΊΠΈ ΠΈ ΠΊΠ°Π΄ΡΠΎΠ²ΡΠΊΠΈ. Π¦Π΅Π»ΡΠ° Π½Π° ΠΎΠ²ΠΎΡ ΡΡΡΠ΄ Π΅ Π΄Π° Π³ΠΎ ΠΏΡΠ΅ΡΡΡΠ°Π²ΠΈ Π΄ΠΈΠ·Π°ΡΠ½ΠΎΡ Π½Π° ΡΠΈΠ·ΠΈΠ±ΠΈΠ»ΠΈΡΠΈ ΡΡΡΠ΄ΠΈΡΠ°ΡΠ° Π·Π° Π²ΠΎΡΠΏΠΎΡΡΠ°Π²ΡΠ²Π°ΡΠ΅ Π½Π° ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²ΠΎ Π½Π° zirconium-89 ΡΠ°Π΄ΠΈΠΎΠΈΠ·ΠΎΡΠΎΠΏ ΠΈ ΠΈΠΌΠΏΠ»Π΅ΠΌΠ΅Π½ΡΠ°ΡΠΈΡΠ° Π½Π° 89Zr-ΡΠ°Π΄ΠΈΠΎΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠΈ Π²ΠΎ ΠΊΠ»ΠΈΠ½ΠΈΡΠΊΠ°ΡΠ° ΠΏΡΠ°ΠΊΡΠ° Π²ΠΎ Π Π΅ΠΏΡΠ±Π»ΠΈΠΊΠ° Π‘Π΅Π²Π΅ΡΠ½Π° ΠΠ°ΠΊΠ΅Π΄ΠΎΠ½ΠΈΡΠ°, ΠΊΠ°ΠΊΠΎ ΠΈ Π΄Π° Π³ΠΈ ΠΏΡΠ΅ΡΡΡΠ°Π²ΠΈ ΡΠ΅Π·ΡΠ»ΡΠ°ΡΠΈΡΠ΅ ΠΎΠ΄ ΠΏΠΎΡΠ΅ΡΠ½ΠΈΡΠ΅ ΡΠ°Π·ΠΈ Π½Π° ΡΡΡΠ΄ΠΈΡΠ°ΡΠ°. ΠΠ²Π°Π° ΡΠΈΠ·ΠΈΠ±ΠΈΠ»ΠΈΡΠΈ ΡΡΡΠ΄ΠΈΡΠ° Π΅ Π΄ΠΈΠ·Π°ΡΠ½ΠΈΡΠ°Π½Π° ΡΠ°ΠΊΠ° ΡΡΠΎ Π²ΠΊΠ»ΡΡΡΠ²Π° ΠΏΡΠ΅Π»ΠΈΠΌΠΈΠ½Π°ΡΠ½Π° Π°Π½Π°Π»ΠΈΠ·Π°, ΠΈΡΡΡΠ°ΠΆΡΠ²Π°ΡΠ΅ Π½Π° ΠΏΠ°Π·Π°ΡΠΎΡ, Π°Π½Π°Π»ΠΈΠ·Π° Π½Π° ΡΠ΅Ρ
Π½ΠΈΡΠΊΠ° ΠΈΠ·Π²ΠΎΠ΄Π»ΠΈΠ²ΠΎΡΡ, Π΅ΠΊΠΎΠ½ΠΎΠΌΡΠΊΠ° Π°Π½Π°Π»ΠΈΠ·Π°, ΠΏΡΠ΅Π³Π»Π΅Π΄ ΠΈ Π°Π½Π°Π»ΠΈΠ·Π° Π½Π° ΡΠΈΡΠ΅ ΠΏΠΎΠ΄Π°ΡΠΎΡΠΈ ΠΈ Π·Π°ΠΊΠ»ΡΡΠΎΠΊ Π·Π° ΡΠΈΠ·ΠΈΠ±ΠΈΠ»Π½ΠΎΡΡ. ΠΠ²Π°Π»ΡΠ°ΡΠΈΡΠ°ΡΠ° Π½Π° ΠΏΠΎΠ΄Π°ΡΠΎΡΠΈΡΠ΅ ΠΎΠ΄ Π°Π½Π°Π»ΠΈΠ·ΠΈΡΠ΅ Π²ΠΎ ΡΠ°ΠΌΠΊΠΈ Π½Π° ΡΠΈΡΠ΅ ΡΠ°Π·ΠΈ Π½Π° ΡΡΡΠ΄ΠΈΡΠ°ΡΠ° Π΅ ΠΏΠΎΡΡΠ΅Π±Π½Π° Π·Π° Π΄Π° ΡΠ΅ ΠΈΠ΄Π΅Π½ΡΠΈΡΠΈΠΊΡΠ²Π°Π°Ρ ΠΏΠΎΠ²ΠΎΠ»Π½ΠΈΡΠ΅ ΠΈ Π½Π΅ΠΏΠΎΠ²ΠΎΠ»Π½ΠΈΡΠ΅ ΡΠ°ΠΊΡΠΎΡΠΈ ΠΈ ΠΎΠΊΠΎΠ»Π½ΠΎΡΡΠΈ Π·Π° Π΄Π° ΡΠ΅ Π΄ΠΎΠ½Π΅ΡΠ΅ ΠΊΠΎΠ½Π΅ΡΠ½Π° ΠΏΡΠΎΡΠ΅Π½ΠΊΠ° Π½Π° ΡΠΈΠ·ΠΈΠ±ΠΈΠ»Π½ΠΎΡΡΠ° Π·Π° Π²ΠΎΡΠΏΠΎΡΡΠ°Π²ΡΠ²Π°ΡΠ΅ Π½Π° ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²ΠΎ Π½Π° zirconium-89 ΡΠ°Π΄ΠΈΠΎΠΈΠ·ΠΎΡΠΎΠΏ ΠΈ 89Zr-ΡΠ°Π΄ΠΈΠΎΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠΈ ΠΈ Π²ΠΎΠ²Π΅Π΄ΡΠ²Π°ΡΠ΅ Π½Π° 89Zr-trastuzumab Π²ΠΎ Π½ΡΠΊΠ»Π΅Π°ΡΠ½ΠΎ-ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠ°ΡΠ° ΠΏΡΠ°ΠΊΡΠ°